NDA 019398 · Otsuka Icu Medcl
Aminosyn-Pf 7%
Amino Acids · Injection · Amino Acid
Last checked: Nov 19, 2026Latest source record: May 24, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Sep 6, 1985
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30,323
6,603 Phase 3, 2,682 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 17, 2025.
INDICATIONS AND USAGE Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with Aminosyn-PF 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes, (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutrition support, and vein tolerance. See DOSAGE AND ADMINISTRATION for additional information. Central Venous Infusion Central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted infants or those requiring long-term parenteral nutrition. Peripheral Parenteral Nutrition For moderately catabolic or depleted patients in whom the central venous route is not indicated, diluted amino acid solutions mixed with 5 to 10% dextrose solutions may be infused by peripheral vein, supplemented, if desired, with fat emulsion.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 6, 1985 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- AMINOSYN-PF 7% · AMINO ACIDS 7% (7GM/100ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Amino Acids" as an intervention, any sponsor and status, largest first.
- Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 YearsPivotal-lookingNot yet recruiting
Tor Biering-SørensenAcademic, hospital or other
NCT07790523 · 410,000 participants (planned) · Start Sep 1, 2026 · Primary completion May 31, 2028
Drug: mCombriax® (mRNA-1083); Efluelda® (TIV-HD) and Spikevax® (mRNA-1273) · For: COVID-19; Influenza
Sites: Hellerup, Denmark; Søborg, Denmark; Santiago de Compostela, Spain
- Community Level Interventions for Pre-eclampsiaPivotal-lookingCompleted
University of British ColumbiaAcademic, hospital or other
NCT01911494 · 87,500 participants (planned) · Start Sep 2013 · Primary completion May 2018
Drug: Magnesium Sulfate; Methyldopa · For: Pre-eclampsia; Hypertension, Pregnancy Induced
Sites: Belagavi, India; Maputo, Mozambique; Sagamu, Nigeria · 4 sites in all
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated DonorsPivotal-lookingRecruiting
Center for International Blood and Marrow Transplant ResearchResearch network
NCT00785525 · 60,000 participants (planned) · Start Feb 1997 · Primary completion Jan 2030
Drug: Filgrastim · For: Healthy
Sites: Boca Raton, Florida; Rockville, Maryland; Minneapolis, Minnesota · 4 sites in all
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy IndividualsPivotal-lookingCompleted
BioNTech SEIndustry
NCT04368728 · 46,969 participants · Start Apr 29, 2020 · Primary completion Feb 10, 2023
Drug: BNT162b1; BNT162b2 and 1 more · For: SARS-CoV-2 Infection; COVID-19
Sites: Athens, Alabama; Birmingham, Alabama; Huntsville, Alabama · 175 sites in all
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19Pivotal-lookingCompleted
Tor Biering-SørensenAcademic, hospital or other
NCT07279766 · 41,060 participants · Start Dec 11, 2025 · Primary completion Aug 26, 2026
Drug: mRNA-1273 (Moderna COVID-19 vaccine) · For: COVID-19
Sites: Hellerup, Denmark; Søborg, Denmark
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over TrialPivotal-lookingNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06567808 · 38,000 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Cefazolin; Vancomycin · For: Infection, Surgical Site
- A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19Pivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT04470427 · 30,415 participants · Start Jul 27, 2020 · Primary completion Dec 29, 2022
Drug: mRNA-1273; Placebo · For: SARS-CoV-2
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 17, 2026
Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03). Shortage of an active ingredient
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- β-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis.
Saunders B, Elliott-Sale K, Artioli GG, et al. · Br J Sports Med 2017 · Meta-Analysis, Systematic Review
- Biomarkers shared by frailty and sarcopenia in older adults: A systematic review and meta-analysis.
Picca A, Coelho-Junior HJ, Calvani R, et al. · Ageing Res Rev 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis.
Guasch-Ferré M, Hruby A, Toledo E, et al. · Diabetes Care 2016 · Meta-Analysis, Systematic Review
- Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies.
Morze J, Wittenbecher C, Schwingshackl L, et al. · Diabetes Care 2022 · Meta-Analysis, Research Support, N.I.H., Extramural
- Nutritional interventions in patients with burn injury: an umbrella review of systematic reviews and meta-analyses of randomised clinical trials.
Naeini F, Zeraattalab-Motlagh S, Rahimlou M, et al. · Br J Nutr 2024 · Systematic Review, Meta-Analysis
- Efficacy of dietary supplements on improving sleep quality: a systematic review and meta-analysis.
Chan V, Lo K · Postgrad Med J 2022 · Meta-Analysis, Systematic Review
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.